Biomedical enterprises want to follow the trend, they need to find the right position based on their own reality

[pharmaceutical network market analysis] in recent years, achievements in the field of biomedicine in China have been emerging, and the whole industry has ushered in new opportunities for development More and more capital is also competing to inject power into this field In 2018, China approved 48 new drugs, including 18 new anti-cancer drugs, an increase of 157% over 2017 Biopharmaceutical development needs to be based on its own actual positioning (photo source: pharmaceutical network) However, biopharmaceutical industry is also highly dependent on policy In recent years, the dramatic changes in the industry are mostly accompanied by policy Whether focusing on innovative R & D or sinking into the grass-roots market, the development of biomedical industry is in line with the policy trend In the face of the influence of policy and the aggravation of competition, biomedical enterprises need to base on their own reality, find a correct position and choose the road suitable for their own development It is understood that in the process of development, some enterprises are constantly combining their own characteristics to find their own development direction For example, Qilu pharmaceutical and Zhengda Tianqing are good at R & D; Tianshili, Baiyunshan, etc try to expand into the field of health; Shanghai Pharmaceutical obtains the commercial operation right of Bayer health "Baijiahei" and other brand drugs in China; jimincredible improves the team construction through marketing incentive mechanisms such as "bottom margin protection + incremental share", "virtual equity"; Fosun Pharmaceutical, etc accelerates with the help of capital Development Through the continuous exploration of the development situation, some enterprises have made some breakthroughs and achievements in the field of biomedicine For example, Hengrui pharmaceutical has been focusing on R & D for many years and is a typical R & D driven enterprise, with an accumulated R & D investment of nearly 10 billion yuan since 2012 According to the data of the first three quarters of 2019, Hengrui pharmaceutical still ranks the top among the A-share pharmaceutical and biological listed companies with R & D expenses of 2.899 billion yuan, and the ratio of R & D expenses to total revenue further increases to 17.11% With continuous high R & D investment, Hengrui pharmaceutical has realized the development from imitation to creation, from domestic to foreign, and gradually formed a virtuous circle of its own performance growth According to the third quarter report data, in the first three quarters of 2019, Hengrui pharmaceutical realized a total operating revenue of 16.945 billion yuan, a year-on-year growth of 36%; realized a net profit attributable to the parent of 3.735 billion yuan, a year-on-year growth of 28.26%, and continued to maintain a stable growth rate In addition, Fosun Pharmaceutical also regards innovation as the core driving force of enterprise development in the development process It is reported that Fosun Pharmaceutical effectively allocates innovation resources around the world and creates its own products and services driven by technological innovation In terms of R & D innovation, Fosun Pharmaceutical "grafts global resources with Chinese power" and actively explores various forms of international cooperation At the same time, it cooperates with the global leader in the field of specialty to establish a joint venture in China For example, it cooperates with kit Pharma, the global leader in the field of cellular immunotherapy, to establish a joint venture in Shanghai to develop car-t cell immunotherapy technology In addition, Fosun Pharmaceutical also directly introduces scientists or technical teams for internal incubation, such as Fosun Pharmaceutical's biological medicine platform Fuhong Hanlin, chemical innovation medicine platform fuchuang medicine, Fosun hongchuang, etc From the perspective of R & D innovation, drug R & D usually has a long cycle and high initial investment Drug companies can not blindly invest, but can consider licensing, R & D outsourcing and other ways In addition, small and medium-sized enterprises can also choose to cooperate with large multinational enterprises and other ways to achieve their own growth In a word, in the process of development, pharmaceutical and biological enterprises should comprehensively consider their own actual situation and make choices within their own capabilities, which should not be blindly followed It is understood that the biomedical industry as a high-end field, the national support policy is very important, and the biomedical industry is a very high industry since the policy It is reported that in terms of the content of the supporting policies, the supporting systems in Shenzhen, Chengdu and Suzhou are relatively complete, covering the support for public platforms, clinical resources, third-party institutions, institutional qualifications, financial services and industry associations, which are worthy of reference for other urban areas that want to focus on the development of biomedical industry Although it is sheltered by the national policy, the enterprises' investment in the field of biomedicine also needs to be combined with their own situation and reasonable investment.